Sign in
TSVT Stock Price, Chart, Stats & News
2seventy bio, Inc.
Save
2seventy bio, Inc. (TSVT) does not currently pay a dividend.
266.14M
Market cap
–
Current P/E
–
Forward P/E
TSVT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 49.84% |
Operating margin | -100.84% |
Pretax margin | -73.53% |
Net margin | -73.53% |
Effective tax rate | – |
ROA | -6.04% |
ROE | -13.31% |
D/E | 1.12x |
Interest coverage ratio | – |
TSVT valuation
P/E | – |
P/S | 6.76x |
P/B | 1.24x |
P/CF | -8.57x |
P/FCF | -8.59x |
P/OCF | -8.57x |
PEG | -0.10x |
EV multiple | -3.49x |
About
2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U. S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma.
Similar securities
Based on sector and market capitalization
Report issue